verecimon

Small moleculeexperimental

Clinical trial activity

12 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
8
Phase 3
4
Phase 4
0

Earliest trial started Aug 1, 2004 (NCT00102921)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1
Mol. weight
444.94 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ccx-282
  • ccx282-b
  • ccx282-b
  • ccx282-b
  • gsk1605786
  • gsk1605786
  • gsk1605786a
  • gsk1605786a
  • gsk1605786a
  • traficet-en
  • vercirnon
  • vercirnon
  • vercirnon
  • vercirnon sodium
  • vercirnon sodium
  • verecimon

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01827631Phase 1May 27, 2013GlaxoSmithKline
NCT01658605Phase 2Feb 1, 2013GlaxoSmithKline
NCT01536418Phase 3Nov 11, 2011GlaxoSmithKline
NCT01489943Phase 1Sep 1, 2011GlaxoSmithKline
NCT01316939Phase 3May 1, 2011GlaxoSmithKline
NCT01318993Phase 3Apr 1, 2011GlaxoSmithKline
NCT01277666Phase 3Dec 1, 2010GlaxoSmithKline
NCT01611805Phase 1Jul 22, 2010GlaxoSmithKline
NCT01114607Phase 1May 1, 2010GlaxoSmithKline
NCT00540657Phase 2Oct 1, 2007ChemoCentryx, University of Tampere
NCT00306215Phase 2Mar 1, 2006ChemoCentryx
NCT00102921Phase 2Aug 1, 2004ChemoCentryx
Showing 12 of 12 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit9932010
ChemoCentryxFor profit3312004
University of TampereAcademic/Hospital1012007
3 organizations
Page 1 / 1